long-acting release drug products for opioid use disorder, chronic pain, and major depressive disorder. Taiwan. 2016. Stemchymal® allogeneic stem cells products. USA. 2018. Immunotherapies for cancer with myeloid checkpoint inhibitors. Taiwan.

Venture and Growth Capital. Overview. Strategies . Overview. ... Healthcare Strategies . We focus on high-potential startups in biotech and pharmaceuticals, med-tech, and digital health care industries, along with broader biomedical and healthcare service sectors. ... primarily in North America and Asia Pacific. We also invest across the ...

Ms. Hsu has 25 years of experience in venture capital, and has participated in the establishment of CDIB Capital Healthcare Ventures and CDIB Capital Healthcare Ventures II since 2012. Career Highlights. Auditor. KPMG. Investment Manager. Central Investment Holding. Senior Vice President.

He joined Kohlberg Kravis Roberts (“KKR”) as a Partner and CEO of Greater China in 2017. Prior to KKR, Paul was President and CEO of CDF and CDIB, as well as the Chairman of CDIB Capital International. Prior to CDF, Paul served as Managing Director at Development Bank of Singapore where he was responsible for DBS Bank’s private equity ...

About Us. Founded in 1959, we have become a leading equity investment and asset management brand in Asia along the way. learn more.

After joining CDF, Mr. Chang helped raise several private equity/ venture capital funds, including RMB CDIB Private Equity (Fujian) Fund, RMB CDIB Yida Private Equity (Kunshan) Fund, and NTD CDIB Capital Healthcare Venture II, and assisted in CDF’s acquisition of KGI Securities in 2012, Cosmos Bank in 2014 and a 25% stake in China Life in 2017.

With an industry-leading international team, we play a pivotal leading role in Taiwan's venture capital and private equity markets This website uses cookies to offer you the best services. By continuing to browse or by clicking Accept, you agree to the storing of cookies on your device for the optimal experience.

Professional Investment Advisory. CDIB’s Strategic Advisory Group started out in 2017 as a team of veteran investment professionals offering advisory services on private equity fund investments and creating tailor-made programs suitable for regional institutional investors. Later that year, CDIB was formally engaged by China Life Insurance ...

XREX is a blockchain-enabled financial institution working with banks, regulators, and users to redefine banking together. XREX provides enterprise-grade banking services to small to medium-sized businesses (SMBs) in or dealing with emerging markets, and novice-friendly financial services to individuals worldwide.

Expertise in Buyout and Private Equity Transactions in APAC. Formerly a 20-year veteran at the Carlyle Group focusing on buyout opportunities in Greater China and Southeast Asia. During his tenure at Carlyle Asia, Alex deployed ~US$2.0 billion equity capital in a wide range of industries spanning from media & telecom to financial services ...